Karyopharm Therapeutics reported $4.04M in Stock for its fiscal quarter ending in December of 2025.





Stock Change Date
AbbVie USD 5.31B 178M Sep/2026
Abbott USD 7.34B 22M Sep/2026
Amgen USD 6.39B 169M Sep/2026
AstraZeneca USD 6.93B 362M Jun/2026
BioCryst Pharmaceuticals USD 13.74M 7.68M Sep/2026
Bristol-Myers Squibb USD 2.7B 33M Sep/2026
Eli Lilly USD 18.19B 1.4B Sep/2026
GlaxoSmithKline GBP 6.28B 125M Jun/2026
Incyte USD 134.25M 21.71M Sep/2026
J&J USD 15.38B 233M Sep/2026
Karyopharm Therapeutics USD 4.04M 72K Dec/2025
MacroGenics USD 9.5M 1.59M Mar/2026
Merck USD 6.16B 43M Sep/2026
Nektar Therapeutics USD 14.46M 1.78M Jun/2024
Novartis USD 6.1B 116M Sep/2026
Novartis USD 6.1B 182M Sep/2026
Pfizer USD 10.02B 77M Sep/2026
Regeneron Pharmaceuticals USD 2.89B 189.7M Sep/2026
Roche Holding CHF 7.6B 9M Jun/2025
Takeda JPY 1.44T 6.17B Sep/2026
TG Therapeutics USD 194.32M 46.35M Sep/2026
Ultragenyx Pharmaceutical USD 59M 0 Sep/2026